Barely Significant
← all excerpts

Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Signal Transduct Target Ther · 2019 · PMC6799843 · PMID 31637013

Europe PMCDOI
1
hedged sentence
0.0260
closest p · 0.5× alpha
0.0260
boldest claim

The sentences

showed a trendp = 0.026actually significant
Combination showed a trend of prolong OS (14 vs 9.5 months; p = 0.026) better than that of lapatinib alone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.